MIF抗体;MIF Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-4: HT-29, Hela and Jurkat cell, Rat brain tissue lysates, Primary antibody: P12789(MIF Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 50 seconds    

  
  

Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine first identified in the 1960s for its ability to inhibit the random migration of macrophages. Over time, MIF has been recognized as a critical regulator of innate and adaptive immunity, inflammation, and cell proliferation. It is secreted by various immune cells, including macrophages, T cells, and endothelial cells, and acts through receptors such as CD74. CXCR2. and CXCR4. MIF exhibits unique enzymatic activity (e.g., tautomerase) and plays dual roles in health and disease, promoting pro-inflammatory responses while also contributing to tissue repair. Dysregulated MIF expression is implicated in autoimmune diseases (e.g., rheumatoid arthritis, lupus), sepsis, cancer, and metabolic disorders, making it a therapeutic target.

MIF antibodies, including monoclonal and polyclonal variants, are essential tools for research and potential clinical applications. They enable detection of MIF in biological samples, inhibition of its signaling pathways, and exploration of its pathological mechanisms. Therapeutic anti-MIF antibodies aim to neutralize its pro-inflammatory or tumor-promoting effects, with preclinical studies showing promise in reducing disease severity in models of inflammation and cancer. However, challenges remain in balancing MIF's beneficial roles (e.g., antimicrobial defense) versus its pathological contributions. Ongoing research focuses on optimizing antibody specificity, delivery, and safety to advance MIF-targeted therapies into clinical trials.